Literature DB >> 23303860

Reduced motoneuron excitability in a rat model of sepsis.

Paul Nardelli1, Jaffar Khan, Randall Powers, Tim C Cope, Mark M Rich.   

Abstract

Many critically ill patients in intensive care units suffer from an infection-induced whole body inflammatory state known as sepsis, which causes severe weakness in patients who survive. The mechanisms by which sepsis triggers intensive care unit-acquired weakness (ICUAW) remain unclear. Currently, research into ICUAW is focused on dysfunction of the peripheral nervous system. During electromyographic studies of patients with ICUAW, we noticed that recruitment was limited to few motor units, which fired at low rates. The reduction in motor unit rate modulation suggested that functional impairment within the central nervous system contributes to ICUAW. To understand better the mechanism underlying reduced firing motor unit firing rates, we moved to the rat cecal ligation and puncture model of sepsis. In isoflurane-anesthetized rats, we studied the response of spinal motoneurons to injected current to determine their capacity for initiating and firing action potentials repetitively. Properties of single action potentials and passive membrane properties of motoneurons from septic rats were normal, suggesting excitability was normal. However, motoneurons exhibited striking dysfunction during repetitive firing. The sustained firing that underlies normal motor unit activity and smooth force generation was slower, more erratic, and often intermittent in septic rats. Our data are the first to suggest that reduced excitability of neurons within the central nervous system may contribute to ICUAW.

Entities:  

Mesh:

Year:  2013        PMID: 23303860      PMCID: PMC3628002          DOI: 10.1152/jn.00936.2012

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  32 in total

1.  Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome.

Authors:  Angela M Cheung; Catherine M Tansey; George Tomlinson; Natalia Diaz-Granados; Andrea Matté; Aiala Barr; Sangeeta Mehta; C David Mazer; Cameron B Guest; Thomas E Stewart; Fatma Al-Saidi; Andrew B Cooper; Deborah Cook; Arthur S Slutsky; Margaret S Herridge
Journal:  Am J Respir Crit Care Med       Date:  2006-06-08       Impact factor: 21.405

2.  Direct muscle stimulation in acute quadriplegic myopathy.

Authors:  M M Rich; S J Bird; E C Raps; L F McCluskey; J W Teener
Journal:  Muscle Nerve       Date:  1997-06       Impact factor: 3.217

3.  Early development of critical illness myopathy and neuropathy in patients with severe sepsis.

Authors:  Jaffar Khan; Taylor B Harrison; Mark M Rich; Marc Moss
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

Review 4.  Neuromuscular manifestations of critical illness.

Authors:  Charles F Bolton
Journal:  Muscle Nerve       Date:  2005-08       Impact factor: 3.217

5.  Mechanisms underlying the early phase of spike frequency adaptation in mouse spinal motoneurones.

Authors:  G B Miles; Y Dai; R M Brownstone
Journal:  J Physiol       Date:  2005-05-05       Impact factor: 5.182

6.  Frequency-current relationships of rat hindlimb alpha-motoneurones.

Authors:  Duane C Button; Kalan Gardiner; Tanguy Marqueste; Phillip F Gardiner
Journal:  J Physiol       Date:  2006-04-13       Impact factor: 5.182

Review 7.  Pathogenesis of septic encephalopathy.

Authors:  Peter Pytel; Jessy J Alexander
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

Review 8.  Active properties of motoneurone dendrites: diffuse descending neuromodulation, focused local inhibition.

Authors:  C J Heckman; Allison S Hyngstrom; Michael D Johnson
Journal:  J Physiol       Date:  2007-10-18       Impact factor: 5.182

Review 9.  Mechanisms of neuromuscular dysfunction in critical illness.

Authors:  Jaffar Khan; Taylor B Harrison; Mark M Rich
Journal:  Crit Care Clin       Date:  2008-01       Impact factor: 3.598

10.  Spontaneous excitation patterns computed for axons with injury-like impairments of sodium channels and Na/K pumps.

Authors:  Na Yu; Catherine E Morris; Béla Joós; André Longtin
Journal:  PLoS Comput Biol       Date:  2012-09-13       Impact factor: 4.475

View more
  7 in total

1.  Increasing motor neuron excitability to treat weakness in sepsis.

Authors:  Paul Nardelli; Randall Powers; Tim C Cope; Mark M Rich
Journal:  Ann Neurol       Date:  2017-12-07       Impact factor: 10.422

Review 2.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

3.  Chronic defects in intraspinal mechanisms of spike encoding by spinal motoneurons following chemotherapy.

Authors:  Stephen N Housley; Paul Nardelli; Randal K Powers; Mark M Rich; Timothy C Cope
Journal:  Exp Neurol       Date:  2020-06-05       Impact factor: 5.330

4.  Reduced motor neuron excitability is an important contributor to weakness in a rat model of sepsis.

Authors:  Paul Nardelli; Jacob A Vincent; Randall Powers; Tim C Cope; Mark M Rich
Journal:  Exp Neurol       Date:  2016-04-24       Impact factor: 5.330

5.  Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?

Authors:  Mark M Rich; Stephen N Housley; Paul Nardelli; Randall K Powers; Timothy C Cope
Journal:  Neuroscientist       Date:  2020-12-21       Impact factor: 7.235

Review 6.  Challenges of neuropathic pain: focus on diabetic neuropathy.

Authors:  Daniela C Rosenberger; Vivian Blechschmidt; Hans Timmerman; André Wolff; Rolf-Detlef Treede
Journal:  J Neural Transm (Vienna)       Date:  2020-02-08       Impact factor: 3.575

7.  Decreased cardiac excitability secondary to reduction of sodium current may be a significant contributor to reduced contractility in a rat model of sepsis.

Authors:  Andrew Koesters; Kathrin L Engisch; Mark M Rich
Journal:  Crit Care       Date:  2014-03-26       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.